Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

Human Vaccines

Volumn 6, Issue 5, 2010, Pages 407-419

  Deschuyteneer, Michel ^a   Elouahabi, Abdelatif ^a   Plainchamp, Dominique ^a   Plisnier, Michel ^a   Soete, Dominique ^a   Corazza, Yvon ^a   Lockman, Laurence ^a   Giannini, Sandra ^a   Deschamps, Marguerite ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Baculovirus; Human papillomavirus; Recombinant; Vaccine; Virus like particles

Indexed keywords

ALUMINUM; PROTEIN L1; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

AMINO ACID ANALYSIS; ARTICLE; CYTOPLASM; DIFFERENTIAL SCANNING CALORIMETRY; DNA BINDING; ELECTRON MICROSCOPY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGOLD ELECTRON MICROSCOPY; IMMUNOGOLD LABELING; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; UTERINE CERVIX CANCER; VIRION; VIRUS PARTICLE; WESTERN BLOTTING;

EID: 77953710988     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.5.11023     Document Type: Article

References (52)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32. (Pubitemid 46986496)
2. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65. (Pubitemid 39488060)
3. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
4. Wheeler CM, Teixeira J, Romanowski B, De Carvalho N, Dubin G, Schuind A. High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16/18 AS04 vaccine). 26th Annual meeting of the European Society for Paedriatric Infectious Diseases, Graz, Austria, May 13-18.
5. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
6. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70:960-5. (Pubitemid 26029013)
7. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997; 22:219-25. (Pubitemid 27187465)
8. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219:37-44.
9. Suzich JA, Ghim S-J, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-7.
10. Christensen ND, Hopfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75:2271-6. (Pubitemid 24282240)
11. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 1999; 17:477-84.
12. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, et al. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 1995; 209:506-18.
13. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Müller M, Jansen KU. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol 1996; 77:465-8.
14. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185:251-7.
15. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997; 71:2988-95.
16. Zhang W, Carmichael J, Ferguson J, Inglis S, Ashrafian H, Stanley M. Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation and self-assembly of virus-like particles in vitro. Virology 1998; 243:423-31.
17. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180-4.
18. Le Cann P, Coursaget P, Iochmann S, Touzé A. Selfassembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 1994; 117:269-74. (Pubitemid 24120636)
19. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993; 67:1936-44. (Pubitemid 23088366)
20. Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaétan J, et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008; 6:427-41.
21. Hu Y-C, Yao K, Wu T-Y. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines 2008; 7:363-71.
22. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res 2006; 68:193-253.
23. Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996; 174:838-41.
24. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006; 193:1223-8.
25. Bird G, O'Donnell M, Moroianu J, Garcea RL. A Possible Role for Cellular Karyopherins in Regulating Polyomavirus and Papillomavirus Capsid Assembly. J Virol 2008; 82:9848-57.
26. Nelson LM, Rose RC, Moroianu J. Nuclear import strategies of high risk HPV16 L1 major capsid protein. J Biol Chem 2002; 277:23958-64.
27. Touzé A, Mahé D, El Mehdaoui S, Dupuy C, Combita-Rojas A-L, Bousarghin L, et al. The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity. FEMS Microbiol Lett 2000; 189:121-7.
28. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, et al. Disassembly and reassembly of yeastderived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 2006; 95:2195-206.
29. Touzé A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998; 26:1317-23.
30. Touzé A, Bousarghin L, Ster C, Combita AL, Roingeard P, Coursaget P. Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J Gen Virol 2001; 82:3005-9.
31. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991; 60:1445-56.
32. Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO J 2002; 21:4754-62.
33. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84.
34. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 2003; 77:11625-32.
35. Bishop B, Dasgupta J, Chen XS. Structure-based engineering of papillomavirus major capsid L1: controlling particle assembly. Virol J 2007; 4:3.
36. Schäfer F, Florin L, Sapp M. DNA binding of L1 is required for human papillomavirus morphogenesis in vivo. Virology 2002; 295:172-81.
37. Meyers C, Mayer TJ, Ozbun MA. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 1997; 71:7381-6.
38. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206:126-35.
39. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000; 5:557-67.
40. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005; 280:13406-14.
41. Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, et al. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2006; 2:147-54.
42. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19.
43. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007; 282:31803-11.
44. Day PM, Thompson CD, Buck CB, Pang Y-YS, Lowy DR, Schiller JT. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 2007; 81:8784-92.
45. Day PM, Gambhira R, Roden RBS, Lowy DR, Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 2008; 82:4638-46.
46. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
47. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71.
48. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7.
49. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72:959-64.
50. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim S-J, Hewitt LA, et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 1999; 73:4882-9.
51. Boyd VL, Bozzini M, Zon G, Noble RL, Mattaliano RJ. Sequencing of peptides and proteins from the carboxy terminus. Anal Biochem 1992; 206:344-52.
52. Samyn B, Hardeman K, Van der Eycken J, Van Beeumen J. Applicability of the alkylation chemistry for chemical C-terminal protein sequence analysis. Anal Chem 2000; 72:1389-99.